WO2003057165A3 - COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF AMYLOID-β PEPTIDE-RELATED DISORDERS - Google Patents

COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF AMYLOID-β PEPTIDE-RELATED DISORDERS Download PDF

Info

Publication number
WO2003057165A3
WO2003057165A3 PCT/US2003/000249 US0300249W WO03057165A3 WO 2003057165 A3 WO2003057165 A3 WO 2003057165A3 US 0300249 W US0300249 W US 0300249W WO 03057165 A3 WO03057165 A3 WO 03057165A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
provides
compositions
secretase
amyloid
Prior art date
Application number
PCT/US2003/000249
Other languages
French (fr)
Other versions
WO2003057165A2 (en
Inventor
William J Netzer
Paul Greengard
Huaxi Xu
Original Assignee
Univ Rockefeller
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Rockefeller filed Critical Univ Rockefeller
Priority to EP03703695A priority Critical patent/EP1469810A4/en
Priority to AU2003206397A priority patent/AU2003206397B2/en
Priority to IL16283803A priority patent/IL162838A0/en
Priority to JP2003557524A priority patent/JP4508645B2/en
Publication of WO2003057165A2 publication Critical patent/WO2003057165A2/en
Publication of WO2003057165A3 publication Critical patent/WO2003057165A3/en
Priority to IL162838A priority patent/IL162838A/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058—Neurological cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Abstract

The present invention provides methods and compositions for modulating levels of amyloid-β peptide (Aβ) exhibited by cells or tissues. The invention also provides pharmaceutical compositions and methods of screening for compounds that modulate Aβ levels. The invention also provides modulation of Aβ levels via selective modulation (e.g., inhibition) of ATP-dependent-Ϝ-secretase activity. The invention also provides methods of preventing, treating or ameliorating the symptoms of a disorder, including but not limited to an Aβ-related disorder, by administering a modulator of Ϝ-secretase, including, but not limited to, a selective inhibitor of ATP-dependent Ϝ-secretase activity or an agent that decreases the formation of active (or optimally active) Ϝ-secretase. The invention also provides the use of inhibitors of ATP-dependent Ϝ-secretase activity to prevent, treat or ameliorate the symptoms of Alzheimer's disease.
PCT/US2003/000249 2002-01-04 2003-01-06 COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF AMYLOID-β PEPTIDE-RELATED DISORDERS WO2003057165A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP03703695A EP1469810A4 (en) 2002-01-04 2003-01-06 Compositions and methods for prevention and treatment of amyloid-beta peptide-related disorders
AU2003206397A AU2003206397B2 (en) 2002-01-04 2003-01-06 Compositions and methods for prevention and treatment of amyloid-beta peptide-related disorders
IL16283803A IL162838A0 (en) 2002-01-04 2003-01-06 Compositions and methods for prevention and treatment peptide-of amyloid- related disorders
JP2003557524A JP4508645B2 (en) 2002-01-04 2003-01-06 Compositions and methods for the prevention and treatment of amyloid-beta peptide related diseases
IL162838A IL162838A (en) 2002-01-04 2004-07-01 Use of compounds modulating an atp-dependent enzymatic activity in compositions for prevention and treatment of amyloid-beta peptide-related disorders

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34500902P 2002-01-04 2002-01-04
US60/345,009 2002-01-04

Publications (2)

Publication Number Publication Date
WO2003057165A2 WO2003057165A2 (en) 2003-07-17
WO2003057165A3 true WO2003057165A3 (en) 2003-11-13

Family

ID=23353081

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/000249 WO2003057165A2 (en) 2002-01-04 2003-01-06 COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF AMYLOID-β PEPTIDE-RELATED DISORDERS

Country Status (6)

Country Link
US (2) US7910586B2 (en)
EP (1) EP1469810A4 (en)
JP (1) JP4508645B2 (en)
AU (1) AU2003206397B2 (en)
IL (2) IL162838A0 (en)
WO (1) WO2003057165A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8859628B2 (en) 2003-02-27 2014-10-14 JoAnne McLaurin Method for preventing, treating and diagnosing disorders of protein aggregation
US9012462B2 (en) 2008-05-21 2015-04-21 Ariad Pharmaceuticals, Inc. Phosphorous derivatives as kinase inhibitors
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003002106A2 (en) 2001-06-29 2003-01-09 Ab Science Use of tyrosine kinase inhibitions for treating allergic diseases
JP2004537537A (en) * 2001-06-29 2004-12-16 アブ サイエンス Uses of tyrosine kinase inhibitors to treat inflammatory diseases
US7727731B2 (en) * 2001-06-29 2010-06-01 Ab Science Potent, selective and non toxic c-kit inhibitors
US20040266797A1 (en) * 2001-06-29 2004-12-30 Alain Moussy Use of potent,selective and non toxic c-kit inhibitors for treating tumor angiogensis
ATE343415T1 (en) * 2001-06-29 2006-11-15 Ab Science THE USE OF C-KIT INHIBITORS FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE
DE60227709D1 (en) * 2001-06-29 2008-08-28 Ab Science THE USE OF C-CRITERIA FOR THE TREATMENT OF AUTOIMMUNE DISEASES
EP1427379B1 (en) * 2001-09-20 2008-08-13 AB Science Use of potent, selective and non toxic c-kit inhibitors for treating interstitial cystitis
JP2005507917A (en) * 2001-09-20 2005-03-24 アブ サイエンス Methods of using tyrosine kinase inhibitors to promote hair growth
EP1469810A4 (en) 2002-01-04 2009-01-14 Univ Rockefeller Compositions and methods for prevention and treatment of amyloid-beta peptide-related disorders
EP1478380B1 (en) * 2002-02-27 2006-08-02 AB Science Use of tyrosine kinase inhibitors for treating cns disorders
WO2004042074A2 (en) * 2002-11-04 2004-05-21 Icogenex Corporation Methods for the identification of agents that modulate the structure and processing of a membrane bound precursor protein
CA2504870A1 (en) * 2002-11-04 2004-05-21 Bioarctic Neuroscience Ab Methods for the identification of agents that modulate the structure and processing of beta-amyloid precursor protein
US20050009849A1 (en) * 2003-01-03 2005-01-13 Veach Darren R. Pyridopyrimidine kinase inhibitors
WO2004099186A1 (en) * 2003-05-06 2004-11-18 Il Yang Pharm Co., Ltd. N-phenyl-2-pyrimidine-amine derivatives and process for the preparation thereof
JPWO2005037316A1 (en) * 2003-10-20 2006-12-28 株式会社ロコモジェン Method for inhibiting secretase activity
GB0325031D0 (en) * 2003-10-27 2003-12-03 Novartis Ag Organic compounds
JP2007509898A (en) 2003-11-03 2007-04-19 プロビオドルグ エージー Useful combinations for the treatment of neurological disorders
EP1713780B1 (en) 2004-02-05 2012-01-18 Probiodrug AG Novel inhibitors of glutaminyl cyclase
US8841326B2 (en) 2004-02-12 2014-09-23 Stc.Unm Therapeutic curcumin derivatives
US20050287519A1 (en) * 2004-05-12 2005-12-29 Merchiers Pascal G Methods, compositions and compound assays for inhibiting amyloid-beta protein production
JP5065017B2 (en) 2004-06-28 2012-10-31 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト Pyrimidines disubstituted at positions 4, 6 and their use as protein kinase inhibitors
US20060084672A1 (en) * 2004-10-20 2006-04-20 The Hospital For Sick Children Method for modification of y-secretase activity through inhibition of Fkbp13
EP1662259A1 (en) * 2004-11-25 2006-05-31 Cellzome Ag Use of Eph receptor inhibitors for the treatment of neurodegenerative diseases
GB0427023D0 (en) 2004-12-09 2005-01-12 Merck Sharp & Dohme Assay method
EP1746092A1 (en) 2005-07-22 2007-01-24 Exonhit Therapeutics SA Compounds and methods for treatment of amyloid-B-peptide related disorders
CA2644093A1 (en) * 2006-03-17 2007-09-27 Herbalscience Singapore Pte. Ltd. Extracts and methods comprising curcuma species
US7922999B2 (en) 2006-04-25 2011-04-12 The Regents Of The University Of California Administration of growth factors for the treatment of CNS disorders
EP2023949A4 (en) * 2006-04-26 2009-08-26 Univ California Compositions and methods for convection enhanced delivery of high molecular weight neurotherapeutics
WO2008070350A2 (en) * 2006-10-27 2008-06-12 The Board Of Regents Of The University Of Texas System Methods and compositions related to wrapping of dehydrons
ES2607794T3 (en) * 2007-06-07 2017-04-04 Intra-Cellular Therapies, Inc. Novel heterocyclic compounds and uses thereof
EP2166858A4 (en) 2007-06-07 2011-08-03 Intra Cellular Therapies Inc Novel heterocycle compounds and uses thereof
AU2009314110C1 (en) * 2008-11-12 2015-04-09 The Washington University Simultaneous measurment of the in vivo metabolism of isoforms of a biomolecule
PL2365804T3 (en) * 2008-11-13 2015-10-30 Modgene Llc Reduction of amyloid-beta load in non-brain tissue
SG10201507362TA (en) * 2009-08-05 2015-10-29 Intra Cellular Therapies Inc Novel Regulatory Proteins And Inhibitors
CA2816957A1 (en) 2010-11-07 2012-05-10 Targegen, Inc. Compositions and methods for treating myelofibrosis
JP5999177B2 (en) 2011-05-04 2016-09-28 アリアド・ファーマシューティカルズ・インコーポレイテッド Compound for inhibiting cell proliferation of EGFR-activated cancer
MX352749B (en) 2011-11-01 2017-12-06 Modgene Llc Compositions and methods for reduction of amyloid-beta load.
CA2911040C (en) * 2012-05-02 2021-11-16 Georgetown University Treating an .alpha.-synucleinopathy with tyrosine kinase inhibitors
JP6469567B2 (en) 2012-05-05 2019-02-13 アリアド・ファーマシューティカルズ・インコーポレイテッド Compound for inhibiting cell proliferation of EGFR-activated cancer
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
CN103922981B (en) * 2014-04-21 2017-01-04 苏州大学 A kind of compound and application thereof
MX2021015390A (en) 2019-06-11 2022-01-24 Sun Pharma Advanced Res Co Ltd Treatment for synucleinopathies.
CA3145864A1 (en) 2019-07-03 2021-01-07 Sumitomo Dainippon Pharma Oncology, Inc. Tyrosine kinase non-receptor 1 (tnk1) inhibitors and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6451838B1 (en) * 2000-05-24 2002-09-17 Pharmacia & Upjohn Company 1-(pyrrolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4052988A (en) 1976-01-12 1977-10-11 Ethicon, Inc. Synthetic absorbable surgical devices of poly-dioxanone
NL7807532A (en) 1978-07-13 1980-01-15 Akzo Nv METAL IMMUNO TEST.
NL8000173A (en) 1980-01-11 1981-08-03 Akzo Nv USE OF WATER-DISPERSIBLE HYDROPHOBIC DYES AS LABELS IN IMMUNOCHEMICAL TESTS.
US4703017C1 (en) 1984-02-14 2001-12-04 Becton Dickinson Co Solid phase assay with visual readout
US4631211A (en) 1985-03-25 1986-12-23 Scripps Clinic & Research Foundation Means for sequential solid phase organic synthesis and methods using the same
AU610083B2 (en) 1986-08-18 1991-05-16 Clinical Technologies Associates, Inc. Delivery systems for pharmacological agents
JPH0664061B2 (en) 1987-02-27 1994-08-22 イーストマン コダック カンパニー Immunoreactive reagents, their method of manufacture and their use for measuring immunoreactive species
EP0280559B1 (en) 1987-02-27 1993-10-20 EASTMAN KODAK COMPANY (a New Jersey corporation) Agglutination immunoassay and kit for determination of a multivalent immune species using a buffered salt wash solution
US4857453A (en) 1987-04-07 1989-08-15 Syntex (U.S.A.) Inc. Immunoassay device
EP1248112A3 (en) 1987-04-27 2004-08-25 Inverness Medical Switzerland GmbH Immunochromatographic specific binding assay device
US5274074A (en) 1987-12-17 1993-12-28 United States Surgical Corporation Medical devices fabricated from homopolymers and copolymers having recurring carbonate units
US5010175A (en) 1988-05-02 1991-04-23 The Regents Of The University Of California General method for producing and selecting peptides with specific properties
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5385915A (en) 1990-05-16 1995-01-31 The Rockefeller University Treatment of amyloidosis associated with Alzheimer disease using modulators of protein phosphorylation
US5139749A (en) 1990-06-22 1992-08-18 Tas, Inc. Fluidized calcining process
US5955444A (en) 1991-08-09 1999-09-21 Massachusetts Institute Of Technology Method of inhibiting abnormal tau hyper phosphorylation in a cell
US5272055A (en) * 1991-12-24 1993-12-21 The University Of Kentucky Research Foundation Detection of Alzheimer's disease and other diseases using a photoaffinity labeling method
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
ES2204921T3 (en) 1993-05-27 2004-05-01 Selectide Corporation SOLID PHASE LIBRARIES CODED, TOPOLOGICALLY SECREGATED.
US5543520A (en) * 1993-10-01 1996-08-06 Ciba-Geigy Corporation Pyrimidine derivatives
AU692484B2 (en) * 1993-10-12 1998-06-11 Du Pont Pharmaceuticals Company 1N-alkyl-N-arylpyrimidinamines and derivatives thereof
US5877399A (en) 1994-01-27 1999-03-02 Johns Hopkins University Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease
IL117923A (en) * 1995-05-03 2000-06-01 Warner Lambert Co Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds
US5620981A (en) * 1995-05-03 1997-04-15 Warner-Lambert Company Pyrido [2,3-D]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation
US5744346A (en) 1995-06-07 1998-04-28 Athena Neurosciences, Inc. β-secretase
US5703200A (en) 1996-03-15 1997-12-30 Ethicon, Inc. Absorbable copolymers and blends of 6,6-dialkyl-1,4-dioxepan-2-one and its cyclic dimer
GB9610964D0 (en) 1996-05-24 1996-07-31 Pharmacia & Upjohn Spa Substituted tetralylmethylen-oxindole analogues as tyrosine kinase inhibitors
JPH10237028A (en) * 1996-12-24 1998-09-08 Chugai Pharmaceut Co Ltd Aromatic amine derivative having nos-inhibiting action
AU742388B2 (en) 1996-12-24 2002-01-03 Chugai Seiyaku Kabushiki Kaisha Aromatic amine derivatives having nos inhibiting action
JP2002510322A (en) * 1997-07-03 2002-04-02 デュポン ファーマシューティカルズ カンパニー Aryl and arylamino-substituted heterocycles as adrenocorticotropic hormone-releasing hormone antagonists
US6440965B1 (en) 1997-10-15 2002-08-27 Krenitsky Pharmaceuticals, Inc. Substituted pyrimidine derivatives, their preparation and their use in the treatment of neurodegenerative or neurological disorders of the central nervous system
US6699671B1 (en) 1998-09-24 2004-03-02 Pharmacia & Upjohn Company Alzheimer's disease secretase, APP substrates therefor, and uses therefor
US20020147197A1 (en) * 1999-10-08 2002-10-10 Newman Michael J. Methods and compositions for enhancing pharmaceutical treatments
WO2001056567A1 (en) * 2000-02-04 2001-08-09 Novo Nordisk A/S 2,4-diaminothiazole derivatives and their use as glycogen synthase kinase-3 (gsk-3) inhibitors
US7087608B2 (en) * 2000-03-03 2006-08-08 Robert Charles Atkins Use of PDGF receptor tyrosine kinase inhibitors for the treatment of diabetic nephropathy
EP1305634A2 (en) 2000-04-03 2003-05-02 Bristol-Myers Squibb Company Fluorescence assay for gamma-secretase activity and inhibitors
AU2001257006A1 (en) 2000-04-11 2001-10-23 Du Pont Pharmaceuticals Company Substituted lactams as inhibitors of abeta protein production
EP1284729A4 (en) 2000-04-13 2007-12-19 Mayo Foundation A(beta)42 lowering agents
EP1305406B2 (en) * 2000-05-11 2014-11-12 Scios Inc. Modulation of gamma-secretase activity
EP1469810A4 (en) 2002-01-04 2009-01-14 Univ Rockefeller Compositions and methods for prevention and treatment of amyloid-beta peptide-related disorders
EP2166858A4 (en) 2007-06-07 2011-08-03 Intra Cellular Therapies Inc Novel heterocycle compounds and uses thereof
ES2607794T3 (en) 2007-06-07 2017-04-04 Intra-Cellular Therapies, Inc. Novel heterocyclic compounds and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6451838B1 (en) * 2000-05-24 2002-09-17 Pharmacia & Upjohn Company 1-(pyrrolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8859628B2 (en) 2003-02-27 2014-10-14 JoAnne McLaurin Method for preventing, treating and diagnosing disorders of protein aggregation
US9012462B2 (en) 2008-05-21 2015-04-21 Ariad Pharmaceuticals, Inc. Phosphorous derivatives as kinase inhibitors
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors

Also Published As

Publication number Publication date
AU2003206397A1 (en) 2003-07-24
US20110312093A1 (en) 2011-12-22
JP4508645B2 (en) 2010-07-21
IL162838A (en) 2016-08-31
IL162838A0 (en) 2005-11-20
JP2005522417A (en) 2005-07-28
US20040028673A1 (en) 2004-02-12
EP1469810A4 (en) 2009-01-14
EP1469810A2 (en) 2004-10-27
US8598171B2 (en) 2013-12-03
WO2003057165A2 (en) 2003-07-17
AU2003206397B2 (en) 2008-07-17
US7910586B2 (en) 2011-03-22

Similar Documents

Publication Publication Date Title
WO2003057165A3 (en) COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF AMYLOID-β PEPTIDE-RELATED DISORDERS
WO2003020702A3 (en) Phosphodiesterase activity and regulation of phosphodiesterase 1-b-mediated signaling in brain
WO2003051313A3 (en) Prevention and treatment of oxidative stress disorders by glutathione and phase ii detoxification enzymes
GB0108592D0 (en) Therapeutic agents
WO2001009118A3 (en) Dithiolthione compounds for the treatment of neurological disorders and for memory enhancement
GB0223040D0 (en) Therapeutic compounds
WO2010057020A3 (en) Modification of amyloid-beta load in non-brain tissue
WO2003083067A8 (en) Histone deacetylase inhibitors for the treatment of multiple sclerosis, amyotrophic lateral sclerosis and alzheimer's disease
EP1562897A4 (en) Phenylcarboxamide beta-secretase inhibitors for the treatment of alzheimer s disease
WO2001062272A3 (en) Soluble tumor necrosis factor receptor and il-4 inhibitor for the treatment of medical disorders
WO2002002190A3 (en) Prevention and treatment of neurodegenerative diseases by glutathione and phase ii detoxification enzymes
WO2006042150A8 (en) Diaminoalkane aspartic protease inhibitors
WO2000008202A3 (en) 3-methylidenyl-2-indolinone modulators of protein kinase
HK1080459A1 (en) Novel pyrimidineamide derivatives and the use thereof
MY138811A (en) Preventive or therapeutic agent for glaucoma
TW200616644A (en) Medicine for prevention or treatment of diabetes
WO2003048122A3 (en) Inhibitors of cytosolic phospholipase a2
WO2001068053A3 (en) Methods and compositions for treating and preventing posterior segment ophthalmic disorders
WO2002079235A3 (en) Compositions and methods for modulating guanylyl cyclase signaling receptor (gc-c) activity and for treating meniere's disease
WO2002100836A3 (en) Compounds, compositions and methods for modulating beta-amyloid production
WO2003099202A3 (en) Beta-secretase inhibitors
PT1656131E (en) Use of betaine for treating intermittent claudication
ATE332688T1 (en) USE OF CARBINOLES FOR THE TREATMENT OF NEUROPATHIC DYSFUNCTION
WO2001037876A3 (en) Methods of ameliorating abnormal bone states
CA2289017A1 (en) The use of a nitroxide or a prodrug thereof in the prophylactic and therapeutic treatment of cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 162838

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2003557524

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2003206397

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2003703695

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003703695

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2003206397

Country of ref document: AU

Date of ref document: 20030106

Kind code of ref document: B